Avapritinib: a new tyrosine kinase inhibitor for treatment of advanced gastrointestinal stromal tumors. The literature review and clinical case
We have three drugs for treatment of gastrointestinal stromal tumors (GIST): imatinib, sunitinib and regorafenib. Avapritinib (Ayvakit, BLU-285) is one more drug that was approved in January 2020. Avapritinib is a new selective tyrosine kinase inhibitor of PDGFRA and KIT mutations. Based on NAVIGATO...
Guardado en:
Autores principales: | Daria A. Filonenko, Bela M. Medvedeva, Andrey A. Meshcheryakov |
---|---|
Formato: | article |
Lenguaje: | RU |
Publicado: |
IP Habib O.N.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/6e46ed6345224af8a1b117b56a28b0d7 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Novel approaches to treating advanced systemic mastocytosis
por: Gilreath JA, et al.
Publicado: (2019) -
Outstanding Response to Sorafenib in a Patient with Metastatic Gastrointestinal Stromal Tumour
por: Charlotte Brinch, et al.
Publicado: (2021) -
Gastrointestinal Stromal Tumors (GISTs): Single Center Experience Observed in a Small Series of Cases
por: Manterola,Carlos, et al.
Publicado: (2016) -
SDH-deficient gastrointestinal stromal tumors: paradoxical effect of imatinib
por: Daria A. Filonenko, et al.
Publicado: (2020) -
Deep Convolutional Neural Networks Detect Tumor Genotype from Pathological Tissue Images in Gastrointestinal Stromal Tumors
por: Cher-Wei Liang, et al.
Publicado: (2021)